The earnings call reflects a positive turnaround for Champions Oncology, highlighted by record revenue, a return to profitability, and successful data licensing deals. However, challenges persist, such as a decline in Q4 revenue and gross margin, alongside ongoing market constraints.

Company Guidance -

Q1 2026

During the Champions Oncology Fourth Quarter Fiscal Year 2025 Earnings Call, the company reported significant growth metrics, highlighting a 14% year-over-year increase in total revenue to a record $57 million, driven by a 4% increase in research services revenue and $4.7 million from data licensing deals. Adjusted EBITDA swung from a loss of $3.9 million in fiscal 2024 to a gain of $7.1 million. The fourth quarter saw a revenue dip to $12.1 million, with an operating loss of $2 million, partially due to $800,000 in noncash expenses. Gross margin for the year improved to 50% from 42%, attributed to high-margin data revenue and operational efficiencies, despite a dip to 41% in Q4. Investments in sales and marketing rose by $500,000, although R&D and G&A expenses saw modest declines. Champions ended the year with $9.8 million in cash, up from $2.6 million, and remains debt-free, projecting cash neutrality in the subsequent quarter. The company remains optimistic about fiscal 2026, anticipating sequential revenue and adjusted EBITDA growth.

Record Revenue and Return to Profitability

Champions Oncology achieved a record total revenue of $57 million, marking a 14% increase from the previous year, and returned to profitability with an adjusted EBITDA of $7.1 million compared to a loss of $3.9 million in fiscal 2024.

Inaugural Data Licensing Deals

Champions closed its first data licensing deal in the third quarter, contributing to a total of $4.7 million in data revenue and showcasing the potential of its multi-omic PDX databank.

Launch of Radiopharmaceutical Services

The company launched a new radiopharmaceutical services platform, offering integrated workflows and therapeutic efficacy testing across a range of isotopes.

Strong Cash Position

Champions ended the year with $9.8 million in cash, up from $2.6 million, and remains debt-free, indicating a strong financial position.

Champions Oncology (CSBR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CSBR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Sep 10, 2025	2026 (Q1)	-0.01 / -	0.11	―	―	―
Jul 23, 2025	2025 (Q4)	-0.20 / -0.07	0.01	-800.00% (-0.08)	―
Mar 11, 2025	2025 (Q3)	-0.01 / 0.36	-0.16	325.00% (+0.52)	―
Dec 11, 2024	2025 (Q2)	0.01 / 0.05	-0.15	133.33% (+0.20)	―
Sep 11, 2024	2025 (Q1)	-0.03 / 0.11	-0.16	168.75% (+0.27)	―
Jul 18, 2024	2024 (Q4)	-0.16 / 0.01	-0.17	105.88% (+0.18)	―
Mar 12, 2024	2024 (Q3)	-0.06 / -0.16	-0.16	0.00% (0.00)	―
Dec 12, 2023	2024 (Q2)	-0.16 / -0.15	0.01	-1600.00% (-0.16)	―
Sep 13, 2023	2024 (Q1)	-0.10 / -0.16	0	―	―
Jul 24, 2023	2023 (Q4)	-0.08 / -0.17	-0.02	-750.00% (-0.15)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CSBR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 23, 2025	$7.75	$6.65	-14.19%
Mar 11, 2025	$8.90	$9.79	+10.00%
Dec 11, 2024	$5.84	$5.16	-11.64%
Sep 11, 2024	$4.07	$4.46	+9.58%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Champions Oncology Inc (CSBR) report earnings?

Champions Oncology Inc (CSBR) is schdueled to report earning on Sep 10, 2025, After Close (Confirmed).

What is Champions Oncology Inc (CSBR) earnings time?

Champions Oncology Inc (CSBR) earnings time is at Sep 10, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CSBR EPS forecast?

CSBR EPS forecast for the fiscal quarter 2026 (Q1) is -0.01.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing